A randomised, double‐blind, placebo‐controlled study to determine the analgesic efficacy, safety and tolerability of VPX638 administered topically to painful wounds.

New analgesics are needed for painful wounds. Multiple reports suggest that topical sevoflurane may have analgesic effects. This placebo‐controlled randomised trial evaluated the analgesic efficacy and safety of VPX638 (topical sevoflurane). Seventy‐eight participants with painful wounds, were enrol...

Full description

Bibliographic Details
Published in:Wound Repair & Regeneration Vol. 33; no. 1; pp. 1 - 12
Main Authors: Golledge, Jonathan, Parra, Sergio, Aldons, Pat M., Frescos, Nicoletta, Iseli, Rebecca K., Pardey, Toni M., Pretorius, Casper F., Shum, Omar R., Yates, Paul A., Bascoul, Cécile B., Doolittle, Dannette K., Rege, Ajay A., Thanawala, Vaidehi J., Giles, Heather, Woodward, Michael C.
Format: research tables/charts randomized controlled trial Journal Article
Published: Wiley-Blackwell Jan/Feb2025
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=183688096&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 183688096
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10671927
        DPV
      jtl: Wound Repair & Regeneration
      issn: 10671927
      maglogo: Y
    pubinfo:
      dt: Jan/Feb2025
      vid: 33
      iid: 1
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        183688096
        183688096
        183688096
        10.1111/wrr.70008
        183688096
      ppf: 1
      ppct: 11
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: A randomised, double‐blind, placebo‐controlled study to determine the analgesic efficacy, safety and tolerability of VPX638 administered topically to painful wounds.
      aug:
        au:
          Golledge, Jonathan
          Parra, Sergio
          Aldons, Pat M.
          Frescos, Nicoletta
          Iseli, Rebecca K.
          Pardey, Toni M.
          Pretorius, Casper F.
          Shum, Omar R.
          Yates, Paul A.
          Bascoul, Cécile B.
          Doolittle, Dannette K.
          Rege, Ajay A.
          Thanawala, Vaidehi J.
          Giles, Heather
          Woodward, Michael C.
        affil: Queensland Research Centre for Peripheral Vascular Disease, James Cook University and Townsville University Hospital and Australian Institute of Tropical Health and Medicine, Townsville Queensland,, Australia
      sug:
        subj:
          Sevoflurane Administration and Dosage
          Administration, Topical
          Wounds, Chronic Drug Therapy
          Wounds, Chronic Complications
          Wound Healing Drug Effects
          Pain Drug Therapy
          Treatment Outcomes
          Human
          Funding Source
          Male
          Female
          Middle Age
          Aged
          Aged, 80 and Over
          Australia
          Randomized Controlled Trials
          Random Assignment
          Double-Blind Studies
          Placebos
          Multicenter Studies
          Descriptive Statistics
          Comparative Studies
          Analgesics, Opioid Therapeutic Use
          Pain Measurement
          Questionnaires
          Middle Aged: 45-64 years
          Aged: 65+ years
          Aged, 80 & over
          Male
          Female
      ab: New analgesics are needed for painful wounds. Multiple reports suggest that topical sevoflurane may have analgesic effects. This placebo‐controlled randomised trial evaluated the analgesic efficacy and safety of VPX638 (topical sevoflurane). Seventy‐eight participants with painful wounds, were enrolled at eight Australian centres and randomly allocated to receive 2 × 5 mL of VPX638 (N = 39) or placebo (N = 40) during one wound dressing change. Numerical pain rating scores and use of opioids were recorded for 24 h. The primary endpoint was pain during wound cleaning, secondary endpoints evaluated pain for 24 h after drug application and opioids use. There was no significant difference in mean pain scores during wound cleaning between VPX638 and placebo (0.854; p = 0.23). The mean differences in summed pain intensity difference from baseline suggested VPX638 provided greater analgesia compared to placebo over 8 h (p < 0.02), 12 h (p < 0.01) and 24 h (p < 0.05) and significantly longer duration of analgesia, 24.3 h for VPX638 versus 7.1 h for placebo (p < 0.01). In the 24 h after drug administration, participants receiving VPX638 had a 50% decrease in opioid use over 24 h compared with placebo. VPX638 appeared safe and well‐tolerated. In conclusion, this small placebo‐controlled randomised trial suggested that VPX638 provides analgesia and is opioid‐sparing for up to 24 h after wound cleaning. It supports the need for further evaluation of the benefit of VPX638 as a topical analgesic for painful wounds.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N